Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.
Aberrant hypermethylation at CpG sites within the CDKN2A gene is associated with silencing and has been proposed as a target for reactivation using both DNA methylation and histone deacetylation inhibitors. This study investigates the role of selecting tumor samples with a silenced as compared to deleted CDKN2A locus when assessing the efficacy of DNA methyltransferase inhibitor, zebularine, combined with the HDAC inhibitor, depsipeptide. Non-small cell lung cancer cell lines with defined CDKN2A status were analyzed by MTS assay to determine the effect of zebularine or zebularine combined with depsipeptide on tumor cell growth. We observed that zebularine treatment resulted in inhibition of cell growth in 11 out of 12 lung cancer cell lines with silenced CDKN2A, but no cell growth inhibition was detected in the 7 lung cancer cell lines tested with deleted CDKN2A (p>0.001). In addition, we found that the combination of 30 microM zebularine and 6 or 7 nM depsipeptide resulted in a synergistic inhibition of cell growth in tumor cells with silenced CDKN2A (p<0.001, CI=0.70 and 0.57, respectively) but not in tumor cells with deleted CDKN2A. In conclusion, tumor cells with methylated CDKN2A are more sensitive to zebularine than cell lines with deleted CDKN2A and the combination of zebularine/depsipeptide results in a synergistic effect on cell growth inhibition that is also linked with the presence of silenced CDKN2A. Thus, combination of DNA methyltransferase and HDAC inhibitors may be a potential treatment for lung cancer patients, but careful selection of patients will be needed to optimize the benefit of this regimen.
Chen
Min
M
Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
Voeller
Donna
D
Marquez
Victor E
VE
Kaye
Frederic J
FJ
Steeg
Patricia S
PS
Giaccone
Giuseppe
G
Zajac-Kaye
Maria
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D018899:CpG Islands; D003562:Cytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D047630:Depsipeptides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017353:Gene Deletion; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D020868:Gene Silencing; D019942:Genes, p16; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D057285:Precision Medicine; D013997:Time Factors
D047630:Depsipeptides; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D003562:Cytidine; C009131:pyrimidin-2-one beta-ribofuranoside; D015254:DNA Modification Methylases
J Biol Chem. 2000 Jan 28;275(4):2727-32
10644736
Blood. 2000 Mar 15;95(6):1942-9
10706859
Mol Cell Biol. 1995 Sep;15(9):5188-95
7651436
Oncogene. 1995 Sep 21;11(6):1211-6
7566983
Clin Cancer Res. 2005 May 15;11(10):3862-8
15897587
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16090-5
16243973
Biochem Pharmacol. 1979 Apr 15;28(8):1443-4
87202
J Med Chem. 1986 Aug;29(8):1374-80
3735306
Blood. 2004 Mar 1;103(5):1635-40
14604977
Nat Rev Drug Discov. 2006 Jan;5(1):37-50
16485345
Oncogene. 2005 Mar 31;24(14):2386-97
15735751
Blood. 1999 Aug 1;94(3):1113-20
10419905
J Natl Cancer Inst. 2003 Mar 5;95(5):399-409
12618505
Exp Hematol. 2007 Feb;35(2):263-73
17258075
J Natl Cancer Inst. 2002 Apr 3;94(7):504-13
11929951
Pharmacol Ther. 1985;30(3):277-86
2433702
Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11797-801
7527544
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6870-5
9618505
Lung Cancer. 2001 Dec;34 Suppl 4:S111-5
11742714
Cancer Prev Res (Phila). 2008 Sep;1(4):233-40
19138966
J Mol Biol. 1999 Feb 19;286(2):389-401
9973559
Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
16341240
Cancer Chemother Pharmacol. 1992;30(1):7-11
1375134
Cancer Res. 2001 Feb 15;61(4):1327-33
11245429
Nat Genet. 1999 Jan;21(1):103-7
9916800
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4
7937876
Cancer Cell. 2004 Aug;6(2):151-8
15324698
Oncogene. 2001 Nov 22;20(53):7787-96
11753657
Blood. 2006 Feb 1;107(3):1174-7
16239434
Cell. 2007 Feb 23;128(4):683-92
17320506
Clin Cancer Res. 2002 Mar;8(3):718-28
11895901
Proc Natl Acad Sci U S A. 1984 Nov;81(22):6993-7
6209710
Int J Cancer. 2008 Jul 1;123(1):8-13
18425818
Cancer J. 2007 Mar-Apr;13(2):105-13
17476138
Cancer J. 2007 Mar-Apr;13(2):80-3
17476134
Mol Cell Biol. 2008 May;28(10):3219-35
18332107
Int J Cancer. 2003 Jan 10;103(2):177-84
12455031
Clin Cancer Res. 2006 Oct 1;12(19):5777-85
17020984
Mol Cell Biol. 2000 Jul;20(14):5276-84
10866684
Cancer Cell. 2004 Apr;5(4):341-51
15093541
Ann N Y Acad Sci. 2005 Nov;1058:246-54
16394141
Br J Cancer. 2000 Sep;83(6):817-25
10952788
Oncogene. 1994 Nov;9(11):3375-8
7936665
J Biol Chem. 1977 Sep 25;252(18):6438-42
893418
Clin Cancer Res. 2008 Feb 1;14(3):826-32
18245545
Mol Cell Biol. 2004 Feb;24(3):1270-8
14729971